Sfoglia per Autore
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
2025-01-01 Lombardi, Pasquale; Kim, Jung Sun; Manfredi, Giulia F.; Celsa, Ciro; Fulgenzi, Claudia A. M.; D'Alessio, Antonio; Stefanini, Bernardo; Doshi, Niraj C.; Warmington, Emily; Marron, Thomas U.; Pinter, Matthias; Scheiner, Bernhard; Kang, Beodeul; Lim, Ho Yeong; Hsu, Wei-Fan; Wietharn, Brooke; Silletta, Marianna; Parisi, Alessandro; Lin, Chun-Yen; Dalbeni, Andrea; Masi, Gianluca; Schönlein, Martin; Von Felden, Johann; Piscaglia, Fabio; Galle, Peter R.; Kudo, Masatoshi; Pressiani, Tiziana; Rimassa, Lorenza; Pirisi, Mario; Cabibbo, Giuseppe; Chon, Hong Jae; Pinato, David J.
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
2025-01-01 Manfredi, Giulia Francesca; Fulgenzi, Claudia Angela Maria; Celsa, Ciro; Stefanini, Bernardo; D'Alessio, Antonio; Pinter, Matthias; Scheiner, Bernhard; Awosika, Nichola; Brunetti, Leonardo; Lombardi, Pasquale; Latchford, Charles; Lee, Pei-Chang; Huang, Yi-Hsiang; Lin, Chun-Yen; Dalbeni, Andrea; Vogel, Arndt; Galle, Peter R.; Kudo, Masatoshi; Rimassa, Lorenza; Chon, Hong Jae; Cabibbo, Giuseppe; Piscaglia, Fabio; Cammà, Calogero; Pillai, Anjana; Pirisi, Mario; Singal, Amit G.; Pinato, David J.
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
2025-01-01 Celsa, Ciro; Di Maria, Gabriele; Lombardi, Pasquale; D'Alessio, Antonio; Fulgenzi, Claudia A M; Brunetti, Leonardo; Manfredi, Giulia F; Stefanini, Bernardo; Sparacino, Alba; Rigamonti, Cristina; Pirisi, Mario; Latchford, Charles; Vaccaro, Marco; Enea, Marco; Cammà, Calogero; Cabibbo, Giuseppe; Pinato, David James
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer
2025-01-01 Pinato, David J; Lombardi, Pasquale; D'Alessio, Antonio; Torkpour, Aria; Fulgenzi, Claudia Angela Maria; Brunetti, Leonardo
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial
2025-01-01 Takada, K.; Takamori, S.; Shimokawa, M.; Pinato, D. J.; Cortellini, A.
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
2024-01-01 Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia Angela Maria; Battaglia, Salvatore; Enea, Marco; Scheiner, Bernhard; D'Alessio, Antonio; Manfredi, Giulia F.; Stefanini, Bernardo; Nishida, Naoshi; Galle, Peter R.; Schulze, Kornelius; Wege, Henning; Ciccia, Roberta; Hsu, Wei-Fan; Vivaldi, Caterina; Wietharn, Brooke; Lin, Ryan Po-Ting; Pirozzi, Angelo; Pressiani, Tiziana; Dalbeni, Andrea; Natola, Leonardo A.; Auriemma, Alessandra; Rigamonti, Cristina; Burlone, Michela; Parisi, Alessandro; Huang, Yi-Hsiang; Lee, Pei-Chang; Ang, Celina; Marron, Thomas U.; Pinter, Matthias; Cheon, Jaekyung; Phen, Samuel; Singal, Amit G; Gampa, Anuhya; Pillai, Anjana; Roehlen, Natascha; Thimme, Robert; Vogel, Arndt; Soror, Noha; Ulahannan, Susanna; Sharma, Rohini; Sacerdoti, David; Pirisi, Mario; Rimassa, Lorenza; Lin, Chun-Yen; Saeed, Anwaar; Masi, Gianluca; Schönlein, Martin; von Felden, Johann; Kudo, Masatoshi; Cortellini, Alessio; Chon, Hong Jae; Cammà, Calogero; Pinato, David James
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
2024-01-01 Celsa, Ciro; Cabibbo, Giuseppe; Pinato, David James
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
2024-01-01 Luke, J. J.; Davar, D.; Andtbacka, R. H.; Bhardwaj, N.; Brody, J. D.; Chesney, J.; Coffin, R.; de Baere, T.; de Gruijl, T. D.; Fury, M.; Goldmacher, G.; Harrington, K. J.; Kaufman, H.; Kelly, C. M.; Khilnani, A. D.; Liu, K.; Loi, S.; Long, G. V.; Melero, I.; Middleton, M.; Neyns, B.; Pinato, D. J.; Sheth, R. A.; Solomon, S. B.; Szapary, P.; Marabelle, A.
Precision Targeting of the Gut Microbiome for Cancer Immunotherapy
2024-01-01 Lombardi, P.; Pinato, D. J.
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
2024-01-01 Korolewicz, James Alexander; Scheiner, Bernhard; Fulgenzi, Claudia A M; D'Alessio, Antonio; Cortellini, Alessio; Pascual, Chynna; Mehan, Aman; Partridge, Sarah; Gujral, Dorothy M; Mohammed, Waleed; Mohammed, Oreoluwa; Grzesiak, Aneta; Booker, Lauren; Cleator, Susan; Pokrovska, Tzveta; Saleem, Waqar; Rackie, James; Needham, Yasmine; Krell, Jonathan; Mcneish, Iain; Tookman, Laura; Park, Won-Ho Edward; Asif, Muzamil; Evans, Joanne S; Pinato, David J
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
2024-01-01 Pinato, D. J.; D'Alessio, A.; Fulgenzi, C. A. M.; Schlaak, A. E.; Celsa, C.; Killmer, S.; Blanco, J. M.; Ward, C.; Stikas, C. -V.; Openshaw, M. R.; Acuti, N.; Nteliopoulos, G.; Balcells, C.; Keun, H. C.; Goldin, R. D.; Ross, P. J.; Cortellini, A.; Thomas, R.; Young, A. -M.; Danckert, N.; Tait, P.; Marchesi, J. R.; Bengsch, B.; Sharma, R.
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
2024-01-01 Rakaee, Mehrdad; Tafavvoghi, Masoud; Ricciuti, Biagio; Alessi, Joao V; Cortellini, Alessio; Citarella, Fabrizio; Nibid, Lorenzo; Perrone, Giuseppe; Adib, Elio; Fulgenzi, Claudia A M; Murilo Hidalgo Filho, Cassio; Di Federico, Alessandro; Jabar, Falah; Hashemi, Sayed; Houda, Ilias; Richardsen, Elin; Rasmussen Busund, Lill-Tove; Donnem, Tom; Bahce, Idris; Pinato, David J; Helland, Åslaug; Sholl, Lynette M; Awad, Mark M; Kwiatkowski, David J
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram
2024-01-01 Losurdo, A.; Dipasquale, A.; Giordano, L.; Persico, P.; Lorenzi, E.; Di Muzio, A.; Barigazzi, C.; Korolewicz, J.; Mehan, A.; Mohammed, O.; Scheiner, B.; Pinato, D. J.; Santoro, A.; Simonelli, M.
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy
2024-01-01 Scheiner, B.; Kang, B.; Balcar, L.; Radu, I. -P.; Reiter, F. P.; Adzic, G.; Guo, J.; Gao, X.; Yuan, X.; Cheng, L.; Gorgulho, J.; Schultheiss, M.; Peeters, F.; Hucke, F.; Ben Khaled, N.; Piseddu, I.; Philipp, A.; Sinner, F.; D'Alessio, A.; Pomej, K.; Saborowski, A.; Bathon, M.; Schwacha-Eipper, B.; Zarka, V.; Lampichler, K.; Nishida, N.; Lee, P. -C.; Krall, A.; Saeed, A.; Himmelsbach, V.; Tesini, G.; Huang, Y. -H.; Vivaldi, C.; Masi, G.; Vogel, A.; Schulze, K.; Trauner, M.; Djanani, A.; Stauber, R.; Kudo, M.; Parikh, N. D.; Dufour, J. -F.; Prejac, J.; Geier, A.; Bengsch, B.; von Felden, J.; Venerito, M.; Weinmann, A.; Peck-Radosavljevic, M.; Finkelmeier, F.; Dekervel, J.; Ji, F.; Wang, H. -W.; Rimassa, L.; Pinato, D. J.; Bouattour, M.; Chon, H. J.; Pinter, M.
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: A systematic review
2024-01-01 Galle, P.; Finn, R. S.; Mitchell, C. R.; Ndirangu, K.; Ramji, Z.; Redhead, G. S.; Pinato, D. J.
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
2024-01-01 Talukder, Rafee; Bakaloudi, Dimitra Rafailia; Makrakis, Dimitrios; Diamantopoulos, Leonidas N; Enright, Thomas; Leary, Jacob B; Raychaudhuri, Ruben; Tripathi, Nishita; Agarwal, Neeraj; Jindal, Tanya; Brown, Jason R; Zakharia, Yousef; Rey-Cárdenas, Macarena; Castellano, Daniel; Nguyen, Charles B; Alva, Ajjai; Zakopoulou, Roubini; Bamias, Aristotelis; Barrera, Rafael Morales; Marmolejo, David; Drakaki, Alexandra; Pinato, David J; Korolewicz, James; Buznego, Lucia Alonso; Duran, Ignacio; Carballeira, Clara Castro; Mckay, Rana R; Stewart, Tyler F; Gupta, Shilpa; Barata, Pedro; Yu, Evan Y; Koshkin, Vadim S; Khaki, Ali Raza; Grivas, Petros
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death
2024-01-01 Cabibbo, Giuseppe; Celsa, Ciro; Battaglia, Salvatore; Enea, Marco; Di Maria, Gabriele; Grova, Alessandro; Ciccia, Roberta; Manfredi, Giulia F; Iavarone, Massimo; Vogel, Arndt; Singal, Amit G; Reig, Maria; Pinato, David J; Cammà, Calogero
Immunotherapy at all stages of hepatocellular carcinoma
2024-01-01 Pinato, D. J.; Fulgenzi, C. A. M.; D'Alessio, A.
Fecal Microbiota Transplantation to Reverse Host-Related Determinants of Resistance to Anticancer Immunotherapy
2024-01-01 D'Arienzo, P. D.; Pinato, D. J.
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction
2024-01-01 Fulgenzi, C. A. M.; Scheiner, B.; D'Alessio, A.; Mehan, A.; Manfredi, G. F.; Celsa, C.; Nishida, N.; Ang, C.; Marron, T. U.; Wu, L.; Saeed, A.; Wietharn, B.; Cammarota, A.; Pressiani, T.; Pinter, M.; Sharma, R.; Cheon, J.; Huang, Y. -H.; Lee, P. -C.; Phen, S.; Gampa, A.; Pillai, A.; Napolitano, A.; Vivaldi, C.; Salani, F.; Masi, G.; Silletta, M.; Lo Prinzi, F.; Di Giacomo, E.; Vincenzi, B.; Bettinger, D.; Thimme, R.; Vogel, A.; Schonlein, M.; Von Felden, J.; Schulze, K.; Wege, H.; Galle, P. R.; Pirisi, M.; Park, J. -W.; Kudo, M.; Rimassa, L.; Singal, A. G.; El Tomb, P.; Ulahannan, S.; Parisi, A.; Chon, H. J.; Hsu, W. -F.; Ghittoni, G.; Camma, C.; Stefanini, B.; Trevisani, F.; Giannini, E. G.; Cortellini, A.; Pinato, D. J.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study | 1-gen-2025 | Lombardi, Pasquale; Kim, Jung Sun; Manfredi, Giulia F.; Celsa, Ciro; Fulgenzi, Claudia A. M.; D'Alessio, Antonio; Stefanini, Bernardo; Doshi, Niraj C.; Warmington, Emily; Marron, Thomas U.; Pinter, Matthias; Scheiner, Bernhard; Kang, Beodeul; Lim, Ho Yeong; Hsu, Wei-Fan; Wietharn, Brooke; Silletta, Marianna; Parisi, Alessandro; Lin, Chun-Yen; Dalbeni, Andrea; Masi, Gianluca; Schönlein, Martin; Von Felden, Johann; Piscaglia, Fabio; Galle, Peter R.; Kudo, Masatoshi; Pressiani, Tiziana; Rimassa, Lorenza; Pirisi, Mario; Cabibbo, Giuseppe; Chon, Hong Jae; Pinato, David J. | |
| Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence | 1-gen-2025 | Manfredi, Giulia Francesca; Fulgenzi, Claudia Angela Maria; Celsa, Ciro; Stefanini, Bernardo; D'Alessio, Antonio; Pinter, Matthias; Scheiner, Bernhard; Awosika, Nichola; Brunetti, Leonardo; Lombardi, Pasquale; Latchford, Charles; Lee, Pei-Chang; Huang, Yi-Hsiang; Lin, Chun-Yen; Dalbeni, Andrea; Vogel, Arndt; Galle, Peter R.; Kudo, Masatoshi; Rimassa, Lorenza; Chon, Hong Jae; Cabibbo, Giuseppe; Piscaglia, Fabio; Cammà, Calogero; Pillai, Anjana; Pirisi, Mario; Singal, Amit G.; Pinato, David J. | |
| Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis | 1-gen-2025 | Celsa, Ciro; Di Maria, Gabriele; Lombardi, Pasquale; D'Alessio, Antonio; Fulgenzi, Claudia A M; Brunetti, Leonardo; Manfredi, Giulia F; Stefanini, Bernardo; Sparacino, Alba; Rigamonti, Cristina; Pirisi, Mario; Latchford, Charles; Vaccaro, Marco; Enea, Marco; Cammà, Calogero; Cabibbo, Giuseppe; Pinato, David James | |
| ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer | 1-gen-2025 | Pinato, David J; Lombardi, Pasquale; D'Alessio, Antonio; Torkpour, Aria; Fulgenzi, Claudia Angela Maria; Brunetti, Leonardo | |
| Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial | 1-gen-2025 | Takada, K.; Takamori, S.; Shimokawa, M.; Pinato, D. J.; Cortellini, A. | |
| Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment | 1-gen-2024 | Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia Angela Maria; Battaglia, Salvatore; Enea, Marco; Scheiner, Bernhard; D'Alessio, Antonio; Manfredi, Giulia F.; Stefanini, Bernardo; Nishida, Naoshi; Galle, Peter R.; Schulze, Kornelius; Wege, Henning; Ciccia, Roberta; Hsu, Wei-Fan; Vivaldi, Caterina; Wietharn, Brooke; Lin, Ryan Po-Ting; Pirozzi, Angelo; Pressiani, Tiziana; Dalbeni, Andrea; Natola, Leonardo A.; Auriemma, Alessandra; Rigamonti, Cristina; Burlone, Michela; Parisi, Alessandro; Huang, Yi-Hsiang; Lee, Pei-Chang; Ang, Celina; Marron, Thomas U.; Pinter, Matthias; Cheon, Jaekyung; Phen, Samuel; Singal, Amit G; Gampa, Anuhya; Pillai, Anjana; Roehlen, Natascha; Thimme, Robert; Vogel, Arndt; Soror, Noha; Ulahannan, Susanna; Sharma, Rohini; Sacerdoti, David; Pirisi, Mario; Rimassa, Lorenza; Lin, Chun-Yen; Saeed, Anwaar; Masi, Gianluca; Schönlein, Martin; von Felden, Johann; Kudo, Masatoshi; Cortellini, Alessio; Chon, Hong Jae; Cammà, Calogero; Pinato, David James | |
| Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment | 1-gen-2024 | Celsa, Ciro; Cabibbo, Giuseppe; Pinato, David James | |
| Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease | 1-gen-2024 | Luke, J. J.; Davar, D.; Andtbacka, R. H.; Bhardwaj, N.; Brody, J. D.; Chesney, J.; Coffin, R.; de Baere, T.; de Gruijl, T. D.; Fury, M.; Goldmacher, G.; Harrington, K. J.; Kaufman, H.; Kelly, C. M.; Khilnani, A. D.; Liu, K.; Loi, S.; Long, G. V.; Melero, I.; Middleton, M.; Neyns, B.; Pinato, D. J.; Sheth, R. A.; Solomon, S. B.; Szapary, P.; Marabelle, A. | |
| Precision Targeting of the Gut Microbiome for Cancer Immunotherapy | 1-gen-2024 | Lombardi, P.; Pinato, D. J. | |
| The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden | 1-gen-2024 | Korolewicz, James Alexander; Scheiner, Bernhard; Fulgenzi, Claudia A M; D'Alessio, Antonio; Cortellini, Alessio; Pascual, Chynna; Mehan, Aman; Partridge, Sarah; Gujral, Dorothy M; Mohammed, Waleed; Mohammed, Oreoluwa; Grzesiak, Aneta; Booker, Lauren; Cleator, Susan; Pokrovska, Tzveta; Saleem, Waqar; Rackie, James; Needham, Yasmine; Krell, Jonathan; Mcneish, Iain; Tookman, Laura; Park, Won-Ho Edward; Asif, Muzamil; Evans, Joanne S; Pinato, David J | |
| Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study | 1-gen-2024 | Pinato, D. J.; D'Alessio, A.; Fulgenzi, C. A. M.; Schlaak, A. E.; Celsa, C.; Killmer, S.; Blanco, J. M.; Ward, C.; Stikas, C. -V.; Openshaw, M. R.; Acuti, N.; Nteliopoulos, G.; Balcells, C.; Keun, H. C.; Goldin, R. D.; Ross, P. J.; Cortellini, A.; Thomas, R.; Young, A. -M.; Danckert, N.; Tait, P.; Marchesi, J. R.; Bengsch, B.; Sharma, R. | |
| Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer | 1-gen-2024 | Rakaee, Mehrdad; Tafavvoghi, Masoud; Ricciuti, Biagio; Alessi, Joao V; Cortellini, Alessio; Citarella, Fabrizio; Nibid, Lorenzo; Perrone, Giuseppe; Adib, Elio; Fulgenzi, Claudia A M; Murilo Hidalgo Filho, Cassio; Di Federico, Alessandro; Jabar, Falah; Hashemi, Sayed; Houda, Ilias; Richardsen, Elin; Rasmussen Busund, Lill-Tove; Donnem, Tom; Bahce, Idris; Pinato, David J; Helland, Åslaug; Sholl, Lynette M; Awad, Mark M; Kwiatkowski, David J | |
| Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram | 1-gen-2024 | Losurdo, A.; Dipasquale, A.; Giordano, L.; Persico, P.; Lorenzi, E.; Di Muzio, A.; Barigazzi, C.; Korolewicz, J.; Mehan, A.; Mohammed, O.; Scheiner, B.; Pinato, D. J.; Santoro, A.; Simonelli, M. | |
| Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy | 1-gen-2024 | Scheiner, B.; Kang, B.; Balcar, L.; Radu, I. -P.; Reiter, F. P.; Adzic, G.; Guo, J.; Gao, X.; Yuan, X.; Cheng, L.; Gorgulho, J.; Schultheiss, M.; Peeters, F.; Hucke, F.; Ben Khaled, N.; Piseddu, I.; Philipp, A.; Sinner, F.; D'Alessio, A.; Pomej, K.; Saborowski, A.; Bathon, M.; Schwacha-Eipper, B.; Zarka, V.; Lampichler, K.; Nishida, N.; Lee, P. -C.; Krall, A.; Saeed, A.; Himmelsbach, V.; Tesini, G.; Huang, Y. -H.; Vivaldi, C.; Masi, G.; Vogel, A.; Schulze, K.; Trauner, M.; Djanani, A.; Stauber, R.; Kudo, M.; Parikh, N. D.; Dufour, J. -F.; Prejac, J.; Geier, A.; Bengsch, B.; von Felden, J.; Venerito, M.; Weinmann, A.; Peck-Radosavljevic, M.; Finkelmeier, F.; Dekervel, J.; Ji, F.; Wang, H. -W.; Rimassa, L.; Pinato, D. J.; Bouattour, M.; Chon, H. J.; Pinter, M. | |
| Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: A systematic review | 1-gen-2024 | Galle, P.; Finn, R. S.; Mitchell, C. R.; Ndirangu, K.; Ramji, Z.; Redhead, G. S.; Pinato, D. J. | |
| Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma | 1-gen-2024 | Talukder, Rafee; Bakaloudi, Dimitra Rafailia; Makrakis, Dimitrios; Diamantopoulos, Leonidas N; Enright, Thomas; Leary, Jacob B; Raychaudhuri, Ruben; Tripathi, Nishita; Agarwal, Neeraj; Jindal, Tanya; Brown, Jason R; Zakharia, Yousef; Rey-Cárdenas, Macarena; Castellano, Daniel; Nguyen, Charles B; Alva, Ajjai; Zakopoulou, Roubini; Bamias, Aristotelis; Barrera, Rafael Morales; Marmolejo, David; Drakaki, Alexandra; Pinato, David J; Korolewicz, James; Buznego, Lucia Alonso; Duran, Ignacio; Carballeira, Clara Castro; Mckay, Rana R; Stewart, Tyler F; Gupta, Shilpa; Barata, Pedro; Yu, Evan Y; Koshkin, Vadim S; Khaki, Ali Raza; Grivas, Petros | |
| Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death | 1-gen-2024 | Cabibbo, Giuseppe; Celsa, Ciro; Battaglia, Salvatore; Enea, Marco; Di Maria, Gabriele; Grova, Alessandro; Ciccia, Roberta; Manfredi, Giulia F; Iavarone, Massimo; Vogel, Arndt; Singal, Amit G; Reig, Maria; Pinato, David J; Cammà, Calogero | |
| Immunotherapy at all stages of hepatocellular carcinoma | 1-gen-2024 | Pinato, D. J.; Fulgenzi, C. A. M.; D'Alessio, A. | |
| Fecal Microbiota Transplantation to Reverse Host-Related Determinants of Resistance to Anticancer Immunotherapy | 1-gen-2024 | D'Arienzo, P. D.; Pinato, D. J. | |
| Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction | 1-gen-2024 | Fulgenzi, C. A. M.; Scheiner, B.; D'Alessio, A.; Mehan, A.; Manfredi, G. F.; Celsa, C.; Nishida, N.; Ang, C.; Marron, T. U.; Wu, L.; Saeed, A.; Wietharn, B.; Cammarota, A.; Pressiani, T.; Pinter, M.; Sharma, R.; Cheon, J.; Huang, Y. -H.; Lee, P. -C.; Phen, S.; Gampa, A.; Pillai, A.; Napolitano, A.; Vivaldi, C.; Salani, F.; Masi, G.; Silletta, M.; Lo Prinzi, F.; Di Giacomo, E.; Vincenzi, B.; Bettinger, D.; Thimme, R.; Vogel, A.; Schonlein, M.; Von Felden, J.; Schulze, K.; Wege, H.; Galle, P. R.; Pirisi, M.; Park, J. -W.; Kudo, M.; Rimassa, L.; Singal, A. G.; El Tomb, P.; Ulahannan, S.; Parisi, A.; Chon, H. J.; Hsu, W. -F.; Ghittoni, G.; Camma, C.; Stefanini, B.; Trevisani, F.; Giannini, E. G.; Cortellini, A.; Pinato, D. J. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile